The exercise capacity of patients with advanced-stage NSCLC is lower due to reduced pulmonary functions and peripheral muscle strength compared to patients with early-stage NSCLC. Therefore, we can conclude that reduced exercise capacity negatively impacts functional categories of health related quality of life of patients with advanced-stage NSCLC.
2047 Background: Enzastaurin, an orally administered potent PKC inhibitor, is an anti-angiogenic agent that also suppresses PI3K/AKT to inhibit tumor cell proliferation and induce tumor cell death. Preclinical data suggest that the combination of enzastaurin and pemetrexed (Alimta) produced additive or synergistic antitumor activity in tumor specimens. This phase 1b study evaluated the safety, pharmacokinetic (PK) interaction, and antitumor activity of enzastaurin when combined with pemetrexed. Methods: Patients (pts) with advanced or metastatic cancer and an ECOG status of 0–2 received an intravenous dose of 500 mg/m2 pemetrexed on day 1 and an oral dose of 500 mg enzastaurin once daily, (after day 4 in cycle 1) in repeat 21-day cycles for up to 6 cycles. In cycle 1, a loading dose of 1200 mg enzastaurin (400 mg/3×/day) was given on day 4. Pts were also given oral folic acid daily and vitamin B12 every 9 weeks for the duration of pemetrexed therapy, and 5–7 days before cycle 1. Results: Blood samples for PK analysis of enzastaurin (n = 21) were collected on day 21 of cycle 1 and day 1 of cycle 2, and for analysis of pemetrexed (n = 22) on day 1 of cycle 1 and cycle 2. Steady-state concentration [geometric mean (%CV)] of total analytes (enzastaurin and its metabolites) was 1270 nM (126%) when administered alone and 1130 nM (100%) when administered with pemetrexed. Thus, no significant differences in exposures were observed when combined with pemetrexed. Clearance of pemetrexed was the same when dosed either with enzastaurin (2.48 L/h/m2) or as a single agent (2.62 L/h/m2). Safety data from the first 2 cycles are consistent with the known toxicity profile of pemetrexed. No grade 3 or 4 toxicity was reported following the loading dose of 1200 mg enzastaurin. Conclusions: Preliminary data suggest that there is no significant PK interaction between enzastaurin and pemetrexed, and that the combination is well tolerated. The current study is ongoing and subsequent analyses will document tumor responses and safety for longer-term treatment of enzastaurin combined with pemetrexed. This first PK study of enzastaurin and pemetrexed will help determine if enzastaurin has an additive clinical benefit to pemetrexed treatment and support future studies in NSCLC and mesothelioma. [Table: see text]
IntroductionInfertility is a condition in which women cannot conceive despite regular sexual intercourse during a year without contraception [1]. The incidence and frequency of infertility varies between societies. A healthy couple normally has 25% chance of conceiving in each ovulation cycle per month.This likelihood of pregnancy is assumed to be 57% for three months, 72% for six months, 85% for twelve months, and 93% for twenty four months. After age 35, quality oocyte production starts decreasing. Assisted Reproductive Techniques (ART) have been developed for infertility related problems and to offer more treatment options with increased infertility rates. Factors such as the age of the patient, etiology, and duration of infertility should always be considered. Infertility treatment should be benefi cial both for the couple and the team that will implement it, when economically more advantageous, effective, and less deleterious protocols are developed. Despite ART progression, pregnancy rates per ART cycles initiated are still around 30% [2]. Follicle-Stimulating Hormone (FSH) and Luteinizing hormones are members of the glycoprotein hormone family that regulate gonadal function and menstrual cycle. The effects of FSH and LH are exerted AbstractAssisted reproductive techniques have been developed for infertility related problems and to offer more treatment options with increased infertility rates. The aim of the study was to investigate the effect of Luteinizing hormone β receptor (LHβR) gene variants on outcome of In Vitro Fertilization (IVF). This study included 69 cases (29 cases with failured of IVF treatment in IVF Center of Ondokuz Mayis University Hospital by comparing with 30 healthy pregnant cases). DNA isolated from all the cases and LHβ gene was analyzed by next generation DNA sequencing method. The statistical analysis was performed by SPSS and Chi-Square analysis. There was no statistically signifi cant difference between patients and control groups for LHβ gene exon 3 mutations of rs1056917 and rs149579838 (p>0.05). When we investigate clinical fi ndings according to the genotype, we found that, GG genotype of rs149579838 (p=0.04, χ²=6.381) and AG genotype of rs1056917 (p=0.03, χ²=6,75) was statistically signifi cant for primary infertile cases. Our results suggest that women who have GG genotype for rs149579838 and AG genotype for rs1056917 are under risk for primary infertility. Large scaled, prospective and randomized trails are needed to demonstrate the relationship between LHβ gene exon 3 mutations and infertility. These results should be confi rmed by further and larger researches groups.ART treatment outcomes [3][4][5][6]. LH, with its receptor located on the cell surface, is important for the theca function, follicle maturation, and ovulation. The LH hormone has beta unit https: //www.peertechz.com/journals/international-journal-of-clinical-endocrinology-and-metabolism Citation: Yılmaz E, Ozdemir A, Onal M, Guven D, Tural S, et al. (2020) Association between LHβR gene variant and infer...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.